Yes, you can prescribe terbinafine to a patient with eGFR 66 mL/min/1.73 m²
Terbinafine can be safely prescribed at standard doses for your patient with an eGFR of 66 mL/min/1.73 m², as this level of kidney function does not require dose adjustment or contraindicate its use.
Key Clinical Reasoning
Your patient's eGFR of 66 mL/min/1.73 m² represents Stage 2 CKD (mildly decreased kidney function), which is well above the threshold where terbinafine becomes problematic.
FDA Labeling Guidance
The FDA drug label explicitly states that terbinafine has not been adequately studied in patients with creatinine clearance ≤50 mL/min 1. Your patient's eGFR of 66 is comfortably above this cutoff, placing them in the safe prescribing range.
Pharmacokinetic Considerations
- Renal clearance is decreased by approximately 50% when creatinine clearance drops to ≤50 mL/min 1
- At eGFR 66, terbinafine clearance remains essentially normal
- Approximately 70% of terbinafine is eliminated renally after extensive hepatic metabolism 1
- The drug is extensively metabolized by multiple CYP enzymes before renal excretion 1
Prescribing Algorithm for Terbinafine Based on Kidney Function
eGFR ≥60 mL/min/1.73 m²: Standard dosing (250 mg daily) - Your patient is here
eGFR 50-59 mL/min/1.73 m²: Standard dosing acceptable, but monitor more closely
eGFR <50 mL/min/1.73 m²: Use not adequately studied; consider alternative antifungal or measure GFR directly if terbinafine is essential
Dialysis: Insufficient data; avoid use
Important Caveats
Guideline Context
While the KDOQI guidelines 2 provide extensive recommendations for antimicrobial dosing in CKD, terbinafine is notably absent from these tables. The antifungal guidance focuses on amphotericin, fluconazole, and flucytosine, with dose adjustments recommended when GFR <60 mL/min/1.73 m² for amphotericin and flucytosine, and <45 mL/min/1.73 m² for fluconazole 2.
Monitoring Recommendations
For your patient with eGFR 66:
- Baseline liver function tests (terbinafine carries hepatotoxicity risk independent of kidney function)
- Monitor eGFR at least annually per CKD guidelines 2
- Reassess if eGFR drops below 50 mL/min/1.73 m² during treatment
- Standard treatment duration applies (6 weeks for fingernails, 12 weeks for toenails)
When to Reconsider
Do not use standard dosing if:
- eGFR drops to <50 mL/min/1.73 m² during treatment
- Acute kidney injury develops
- Patient develops hepatic impairment (clearance also reduced ~50% in cirrhosis) 1
The absence of terbinafine from major CKD prescribing guidelines combined with the FDA's clear threshold of creatinine clearance ≤50 mL/min provides straightforward guidance: your patient with eGFR 66 is safely above the concern threshold and can receive standard terbinafine dosing.